Sun Pharmaceuticals Industries Ltd Analyst Rating
based on 37 analysts
73.68%
Buy
18.42%
Hold
7.89%
Sell
Based on 37 analysts offering long term price targets for Sun Pharmaceuticals Industries Ltd. An average target of ₹2047.11
Source: S&P Global Market Intelligence
Sun Pharmaceuticals Industries Ltd Share analysis
Sun Pharmaceuticals Industries Ltd price forecast by 37 analysts
Upside of13.17%
High
₹2450
Target
₹2047.11
Low
₹1600
Sun Pharmaceuticals Industries Ltd target price ₹2047.11, a slight upside of 13.17% compared to current price of ₹1814.6. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharmaceuticals Industries Ltd revenue growth forecast
Expected growth rate Q1, FY2026:20.98%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharmaceuticals Industries Ltd EPS growth forecast
EPS estimate Q1, FY2026:38.69%
Forecast
Actual
Source: S&P Global Market Intelligence
Sun Pharmaceuticals Industries Ltd Performance
Day's Low
Day's High
₹1,796.65Day's Price Range₹1,82852 Week's Low
52 Week's High
₹1,208.5552-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | + 0.55 % |
| 3 Month Return | -2.89 % |
| 1 Year Return | + 45 % |
| Market Stats | |
| Previous Close | ₹1,808.85 |
| Open | ₹1,811.00 |
| Volume | 12.99L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹4,34,003.71Cr |
Sun Pharmaceuticals Industries Ltd Key Statistics
| P/E Ratio | 39.55 |
| PEG Ratio | 3.77 |
| Market Cap | ₹4,34,003.71 Cr |
| P/B Ratio | 16.41 |
| EPS | 40.21 |
| Dividend Yield | 0.83 |
| Sector | Pharmaceuticals |
| ROE | 12.05 |
Sun Pharmaceuticals Industries Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,34,003.71 Cr | 64.45% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,55,212.84 Cr | 44.67% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,16,318.47 Cr | 53.62% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹40,334.16 Cr | 3.52% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹29,198.95 Cr | -0.52% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Sun Pharmaceuticals Industries Ltd Mutual Fund Holdings
About Sun Pharmaceuticals Industries Ltd
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Share Price: ₹1814.60 per share as on 23 Dec, 2024 04:01 PM
Market Capitalisation: ₹4,34,003.71Cr as of today
Revenue: ₹13,264.22Cr as on September 2024 (Q3 24)
Net Profit: ₹3,030.67Cr as on September 2024 (Q3 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharmaceuticals Industries Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Sun Pharmaceuticals Industries Ltd
Sun Pharma Faces Setbacks but Remains Recommended - 20 Dec, 2024
Sun Pharmaceutical Industries is recommended by HDFC Securities for 2025. The company recently acquired a stake in Pharmazz Inc but faces a court injunction on Leqselvi's launch.Sun Pharma Benefits from Incentive Schemes - 19 Dec, 2024
Sun Pharmaceuticals Industries Ltd is listed among the top beneficiaries of government incentive schemes, receiving significant financial support ranging from Rs 150 crore to Rs 330 crore.Vidhi Sanghvi: Rising Star in Pharmaceuticals - 18 Dec, 2024
Vidhi Sanghvi, daughter of billionaire Dilip Shanghvi, is trending as a key figure in Sun Pharmaceutical Industries, leading consumer healthcare and nutrition. Under her leadership, the company has become a global leader in specialty generics, with revenues of $5.4 billion and a presence in over 100 countries.Sun Pharma Stock Sees Significant Volume Surge - 16 Dec, 2024
On December 16, 2024, Sun Pharma Advanced Research Company Ltd experienced a notable volume increase, with 2.23 lakh shares traded, an 8.53-fold rise over the two-week average. The stock price rose by 9.15% to Rs. 231.45.Sun Pharma Faces Customs Fine but Impact Minimal - 14 Dec, 2024
Sun Pharmaceutical has been fined ₹65 lakh by customs for short payment of duties, including a ₹40 lakh penalty and ₹25.2 lakh under the Customs Act. The company stated that this action does not significantly impact its operations or finances.Sun Pharma's Strategic Moves and Positive Outlook - 11 Dec, 2024
Sun Pharmaceuticals is set to amalgamate five subsidiaries and has received a positive outlook from HSBC, projecting strong performance despite upcoming gRevlimid sales losses.Jefferies Projects $100 Million Sales for Sun Pharma - 09 Dec, 2024
Jefferies estimates Sun Pharmaceutical Industries could achieve peak sales of $100 million from new cancer treatment assets, reaffirming a Buy rating with a target price of ₹2150.Sun Pharma Reports Strong Q2FY25 Earnings Growth - 03 Dec, 2024
Sun Pharmaceutical Industries announced a 28% year-on-year increase in consolidated net profit for Q2FY25, reaching ₹3,040.16 crore. Revenue rose nearly 10.5% to ₹13,264.22 crore, reflecting strong operational performance.Sun Pharma Stock Rises Amid Penalties Announcement - 29 Nov, 2024
Sun Pharmaceutical Industries saw a 2.94% stock increase, adding Rs 12,220 crore to its market cap. However, the Ministry of Corporate Affairs imposed penalties on directors for non-disclosure of related-party transactions.Sun Pharma Faces Penalties for Compliance Violations - 28 Nov, 2024
Sun Pharmaceutical Industries Ltd has been penalized by the Ministry of Corporate Affairs for non-disclosure and failing to obtain necessary approvals for related party transactions between 2014 and 2019. Key officials, including CMD Dilip Shanghvi, face fines totaling over Rs 45 lakh. This follows a previous SEBI investigation settled in 2021 without admission of guilt.Sun Pharma Faces Significant Customs Penalties - 26 Nov, 2024
The Office of the Commissioner of Customs has imposed a redemption fine of ₹27 lakh and a penalty of ₹1.25 crore on Sun Pharmaceutical Industries Limited for violations of the Customs Act.
Insights on Sun Pharmaceuticals Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 17.23% to 18.02% in Sep 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 7 quarters, 1.98K Cr → 3.04K Cr (in ₹), with an average increase of 6.8% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 12.58K Cr → 13.64K Cr (in ₹), with an average increase of 4.0% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 51.3% return, outperforming this stock by 6.3%
NEGATIVE IMPACTPrice Dip
In the last 7 days, SUNPHARMA stock has moved down by -0.1%
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 12.78% to 12.11% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 9.01% to 8.89% in Sep 2024 quarter
News
Weight-loss Drugs: A Game Changer for India's Top Pharma Companies
Cipla, one of Indias most well-established pharmaceutical companies, is focusing its efforts on the development of a generic version of Wegovy (semaglutide), an obesity treatment developed by Novo Nordisk. Cipla plans to bring a more affordable alternative to the Indian market, which could significantly increase access to treatment for those struggling with obesity.23 Dec, 2024 10:29 AMIndia’s CDSCO Approves 19 New Drugs in 2024
Cipla Ltd also got the CDSCO approval to market a novel antibiotic - plazomicin, a key development in solving anti-microbial resistance. Cipla USA Inc., a subsidiary of Cipla, holds the patent for plazomicin sulfate, administered once daily. The company possesses global rights for this molecule, excluding Greater China, and is the innovator of the ZEMDRI brand. Orchid Pharma has teamed up with domestic major Cipla Ltd to sell the drug in various markets.22 Dec, 2024 09:38 AMCipla's Big Bet on Diabetes Care with Inhalable Insulin
Cipla, Indias third largest drug maker by market share, is taking an audacious bet on this enormous unmet medical need. Recently, the company announced that it has received the government approval to sell Afrezza, an insulin that can be inhaled from the mouth.21 Dec, 2024 01:08 AMSun Pharmaceuticals Industries Ltd Financials
Index Inclusions
Sun Pharmaceuticals Industries Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.02% | 4.60 | |
| Mutual Funds | 12.11% | ||
| Retail Investors | 8.89% | ||
| Others | 6.5% |
Sun Pharmaceuticals Industries Ltd Key Indicators
Sun Pharmaceuticals Industries Ltd Valuation
Sun Pharmaceuticals Industries Ltd in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (39.55x)
December 19, 2024
Industry (56.23x)
December 19, 2024
Highest (184.63x)
August 28, 2020
Sun Pharmaceuticals Industries Ltd Earnings and Dividends
Sun Pharmaceuticals Industries Ltd Earnings Results
Sun Pharmaceuticals Industries Ltd’s net profit jumped 27.98% since last year same period to ₹3,040.16Cr in the Q2 2024-2025. On a quarterly growth basis, Sun Pharmaceuticals Industries Ltd has generated 7.21% jump in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceuticals Industries Ltd Dividends May,2024
In the quarter ending March 2024, Sun Pharmaceuticals Industries Ltd has declared dividend of ₹5 - translating a dividend yield of 0.97%.
Read More about Dividends
Sun Pharmaceuticals Industries Ltd Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceuticals Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Sun Pharmaceuticals Industries Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Sun Pharmaceuticals Industries Ltd shares.
Sun Pharmaceuticals Industries Ltd (SUNPHARMA) share price today is ₹1814.6
Sun Pharmaceuticals Industries Ltd is listed on NSE
Sun Pharmaceuticals Industries Ltd is listed on BSE
- Today’s highest price of Sun Pharmaceuticals Industries Ltd is ₹1828.
- Today’s lowest price of Sun Pharmaceuticals Industries Ltd is ₹1796.65.
PE Ratio of Sun Pharmaceuticals Industries Ltd is 39.55
PE ratio = Sun Pharmaceuticals Industries Ltd Market price per share / Sun Pharmaceuticals Industries Ltd Earnings per share
Today’s traded volume of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is 12.99L.
Today’s market capitalisation of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is ₹434003.71Cr.
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Price |
|---|---|
52 Week High | ₹1960.35 |
52 Week Low | ₹1208.55 |
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1814.6. It is down -7.43% from its 52 Week High price of ₹1960.35
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1814.6. It is up 50.15% from its 52 Week Low price of ₹1208.55
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Returns |
|---|---|
1 Day Returns | 5.75% |
1 Month Returns | 0.55% |
3 Month Returns | -2.89% |
1 Year Returns | 45% |